Lipids & metabolic liver disease
Obicetrapib for dyslipidemia with or without cardiovascular risk: A GRADE ‐assessed meta‐analysis of randomized trials with trial sequential evidence
Pooled result · LDL-CResult — go to the resultMD −27.66 mg/dL 95% CI −33.62 to −21.70Authors' conclusion
Obicetrapib provides substantial improvements in lipid parameters with a favourable short-term adverse events rate. These results support its role as a potential adjunctive lipid-lowering agent irrespective of ASCVD risk. Longer-term trials are warranted to confirm its durability, cardiovascular outcomes, and safety.
Study context
- Population
- Adults with dyslipidemia, with or without atherosclerotic cardiovascular disease risk; Randomized controlled trials (RCTs) from PubMed, Cochrane, Scopus and Web of Science up to June 2025
- Participants
- 3,399 adults6 RCTs
- Comparison
- Obicetrapib vs placebo
- Outcome
- LDL-C
- Follow-up
- 8-12 weeks
Methodological detailsGRADE-assessed, trial sequential analysis
- GRADE-assessed
- Trial sequential analysis
Pooled result
As reported in the abstract
MD
−27.66 mg/dL
95% CI −33.62 to −21.70
P < 0.0001
Obicetrapibvs Placebo
MD −27.66 mg/dL (95% CI −33.62 to −21.70); P < 0.0001
Further pooled results
| Outcome | MD (mg/dL) (95% CI) | P value | |
|---|---|---|---|
| Non-HDL-C(−28.08%) | −35.41 (−39.42 to −31.39) | P < 0.0001 | |
| HDL-C(141.7%) | 70.85 (62.56–79.15) | P < 0.0001 | |
| −50050100Difference, mg/dL (linear scale) |
| Outcome | RR (95% CI) | |
|---|---|---|
| LDL-C target <55 mg/dL achieved | 6.42 (5.15–8.01) | |
| 0.10.31310Relative risk (log scale) |
| Outcome | RR | P value |
|---|---|---|
| LDL-C target <70 mg/dL achieved | 2.56 | P < 0.0001 |
| LDL-C target <100 mg/dL achieved | 1.34 | P < 0.0001 |
Safety
| Outcome | P value |
|---|---|
| Total adverse eventsNo significant difference | P = 0.41 |
| Serious adverse eventsNo significant difference | P = 0.37 |
Original publication
Obicetrapib for dyslipidemia with or without cardiovascular risk: A GRADE ‐assessed meta‐analysis of randomized trials with trial sequential evidence. Diabetes Obes Metab. Published 25 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →